跳至主要内容
临床试验/EUCTR2006-002582-39-IT
EUCTR2006-002582-39-IT进行中(未招募)不适用

A multicenter, randomized, prospective, controlled study to evaluate the efficacy and the tolerability of a switch to a two different-dosed, nevirapine-based HAARTs in HIV-1 infected patients with undetectable plasma viremia. - SNODO

FONDAZIONE NADIR ONLUS0 个研究点目标入组 200 人开始时间: 2006年8月30日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • HIV-1 documented infection Age 18 and 65 years Current therapy with a HAART including 1 PI ritonavir and 2 NRTIs Any CD4 cell count see exclusion criteria for female patients Plasma HIV-RNA 50 copies/mL for at least 6 months before randomization Stable clinical conditions
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Active opportunistic infections, neoplasms, acute viral hepatitis, drug or alcohol abuse. Chronic hepatitis caused by HBV od HCV is not a cause for exclusion CD4 cell count 250 cells/microliter in female subjects Unability to give and/or to maintain an informed consent Previous NNRTI treatment that was discontinued due to virologic failure Previous nevirapine treatment that was discontinued due to intolerance and/or toxicity

研究者

发起方
FONDAZIONE NADIR ONLUS

相似试验